About the RETAIN study: Improving RETention and viral load outcomes for people taking Antiretroviral therapy through early IdentificatioN of missed doses

Too few South Africans living with HIV achieve viral suppression. Although advances in antiretroviral therapy (ART) have reduced illness and death for people with HIV (PWH), ongoing evidence show gaps in the HIV continuum, including poor tablet taking / adherence and low retention in care, particularly in the first 4 months after ART is started.…

Africa REACH welcomes news that Zimbabwe becomes the first African country to approve injectable PrEP

*This article is based off a press release distributed by DTHF partner, Africa REACH.   The Medicines Control Authority of Zimbabwe recently approved the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV prevention, making Zimbabwe the first African country to authorize the once-every-two-months injectable PrEP drug. Zimbabwe has a PrEP program…

PURPOSE 2 – Join this PrEP Trial

Are you a man or a transgender person who has sex with men? We want to talk to you!   Globally HIV transmission is still a serious health issue that needs a lot of attention from governments, health care providers, and our communities. There are general services, educational campaigns and programmes for all members of…

FASTPrEP Project Kicks Off in Cape Town

Adolescent girls and young women remain at disproportionately high risk of HIV infection in Sub-Saharan Africa. Pre-exposure prophylaxis (PrEP) is an effective biomedical tool to prevent HIV infection but uptake and continued use by key risk groups such as adolescent girls and young women (AGYW) and men who have sex with men (MSM), has so…